Abstract

BackgroundTo investigate the expression and role of special AT-rich sequence-binding protein-2 (SATB2) in laryngeal squamous cell carcinoma (LSCC) tissue and cell line (HEp2), and to evaluate the clinical and prognostic significance of SATB2 protein in patients with LSCC.MethodsThe expression of SATB2 was examined in LSCC tissue and HEp2 cells by Western-blotting, Real-time PCR and immunohistochemical staining. Cell growth curve assay and colony formation assay were used to verify the effect of SATB2 on the proliferation and tumor progression ability of HEp2 cells. Tumor formation assay in nude mice was used to analyze the effect of SATB2 on the tumorigenicity of HEp2 cells.ResultsThe status of SATB2 protein in carcinoma tissues is much lower than that in paracarcinoma tissues. The overall survival of the patients with high SATB2 expression was significantly higher than the low SATB2 expression group. Lower or negative SATB2 expression was significantly correlated with advanced clinical staging, histological grade and tumor recurrence. In vitro experiments demonstrated that over-expression of SATB2 in HEp2 cells inhibited cell proliferation and tumor progression ability, and down-regulation of SATB2 showed the opposite effects. Over-expression of SATB2 repressed the tumorigenicity of HEp2 cells by in vivo experiments. Moreover, multivariate analysis suggested that SATB2 expression might be an independent prognostic indicator for the survival of LSCC patients after curative surgery.ConclusionsSATB2 might involve in the development and progression of LSCC as a tumor suppressor, and thereby may be a valuable prognostic marker for LSCC patients.

Highlights

  • Laryngeal squamous cell carcinoma (LSCC) is the second most frequent malignancy in head and neck region, accounting for 2% of all human malignancies [1,2,3]

  • To explore the exact role of SATB2 in laryngeal squamous cell carcinoma (LSCC), we investigated whether the expression of SATB2 protein is different between tumor tissues and normal tissues, whether SATB2 has any role in the development and progression of LSCC, and whether SATB2 is a prognostic factor in LSCC after curative surgical treatment

  • The Expression of SATB2 in LSCC Tissues To determine the expression of SATB2 protein in LSCC tissues, Western blotting was performed in 14 LSCC tissues with paired non-cancerous mucosa

Read more

Summary

Introduction

Laryngeal squamous cell carcinoma (LSCC) is the second most frequent malignancy in head and neck region, accounting for 2% of all human malignancies [1,2,3]. Current methods used to predict the outcome of LSCC patients mainly depend on the clinicopathological factors, such as TNM stage, differentiation grade and metastasis [5,6,7,8,9,10]. Other parameters such as molecular markers are needed to more accurately predict the outcome of this disease. It is of great value in further understanding the molecular mechanisms of LSCC and find valuable early molecular diagnostic markers and molecular prognostic factors with high specificity and sensitivity and novel therapeutic strategies. To investigate the expression and role of special AT-rich sequence-binding protein-2 (SATB2) in laryngeal squamous cell carcinoma (LSCC) tissue and cell line (HEp2), and to evaluate the clinical and prognostic significance of SATB2 protein in patients with LSCC

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call